vTv Therapeutics Inc. (VTVT): R&D Expense
$17.86M
Year ended 2025-12-31
$28.68M
Trailing 12 months to 2026-06-30
+13.1%
3-year compound annual growth
+10.1%
5-year compound annual growth
-4.1%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $17.86M | +54.7% | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | $11.55M | -15.1% | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | $13.60M | +10.0% | 2026-03-10, From 2023-01-01 |
| 2022-12-31 | $12.36M | -7.3% | 2025-03-20, From 2022-01-01 |
| 2021-12-31 | $13.32M | +21.0% | 2024-03-13, From 2021-01-01 |
| 2020-12-31 | $11.02M | -27.1% | 2023-03-06, From 2020-01-01 |
| 2019-12-31 | $15.12M | -34.4% | 2022-03-29, From 2019-01-01 |
| 2018-12-31 | $23.04M | -41.9% | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $39.64M | -11.8% | 2020-02-21, From 2017-01-01 |
| 2016-12-31 | $44.95M | +65.0% | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | $27.24M | +56.7% | 2018-02-27, From 2015-01-01 |
| 2014-12-31 | $17.38M | -22.0% | 2017-02-24, From 2014-01-01 |
| 2013-12-31 | $22.29M | n/a | 2016-03-04, From 2013-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| vTv Therapeutics Inc. (VTVT) | 2025-12-31 | $17.86M | +54.7% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.94B | +3.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $9.95B | -10.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $13.34B | +21.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $10.44B | -3.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $14.66B | -14.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $15.79B | -12.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare VTVT, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗